Karboplatin Medac

Carboplatin, the active ingredient in Karboplatin Medac, is a platinum coordination complex presented as an injectable solution for intravenous use. It treats various solid tumors, including ovarian, non‑small cell lung, head and neck, and urothelial cancers, typically as part of combination chemotherapy regimens. It is administered under strict medical supervision and requires careful monitoring of renal function and blood counts.

GNH USA supplies Karboplatin Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring quality‑assured product availability across multiple regulatory markets.

Carboplatin is a platinum‑based chemotherapy agent used in the treatment of solid tumours. - Ovarian cancer: used in combination regimens to improve response rates and progression‑free survival. - Non‑small cell lung cancer: incorporated into first‑line or maintenance therapy to enhance disease control. - Head and neck cancer: administered with radiotherapy or other agents to increase local control. - Urothelial carcinoma: employed in systemic therapy for advanced disease to extend survival.

Adverse reactions may occur with carboplatin therapy.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Fatigue: generalized tiredness affecting daily activities. - Anemia: reduced red blood cell count leading to weakness. - Thrombocytopenia: lowered platelet levels increasing bleeding risk. - Neutropenia: decreased neutrophils predisposing to infection. - Electrolyte disturbances: changes in sodium, potassium, or magnesium.

Serious or Rare Side Effects: - Nephrotoxicity: impaired kidney function requiring monitoring. - Ototoxicity: hearing loss or tinnitus, especially at high doses. - Severe allergic reactions: anaphylaxis or hypersensitivity. - Bone marrow aplasia: profound pancytopenia needing supportive care. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Secondary malignancies: rare risk of therapy‑related cancers.

Careful assessment and monitoring are essential when using carboplatin. - Renal function assessment: evaluate baseline creatinine clearance before each cycle. - Hematologic monitoring: perform regular complete blood counts to detect cytopenias. - Hydration status: ensure adequate fluid intake to support renal clearance. - Pregnancy and lactation: avoid use unless benefits outweigh potential fetal or infant risks. - Drug-specific contraindications: do not administer to patients with known hypersensitivity to platinum compounds. - Store at ambient temperature: keep in original container, protect from light and moisture.

Carboplatin may interact with other medicines, affecting safety and efficacy.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increased risk of nephrotoxicity. - Mannitol: may potentiate renal damage when co‑administered. - High‑dose radiation therapy: heightened tissue toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: may alter electrolyte balance and renal clearance. - Antiemetics such as ondansetron: can affect carboplatin metabolism and require dose adjustments.